Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 82, Issue 1, Pages 41-47Publisher
WILEY
DOI: 10.1038/sj.clpt.6100152
Keywords
-
Categories
Ask authors/readers for more resources
The influence of CYP2D6 genotype and CYP2D6 inhibitors on enantiomeric plasma levels of tramadol and O-clesmethyltramadol as well as response to tramadol was investigated. One hundred and seventy-four patients received one hundred intravenous tramadol 3 mg/kg for postoperative analgesia. Blood samples drawn 30, 90, and 180 min after administration were analyzed for plasma concentrations of the enantiomers (+)-, (-)tramadol and (+)-, (-)O-desmethyltramadol by liquid chromatography-tandem mass spectrometry. Different CYP2D6 genotypes displaying zero (poor metabolizer (PM)), one (heterozygous individual (HZ)/intermediate metabolizer (IM)), two extensive metabolizer (EM), and three (ultra rapid metabolizer (UM)) active genes were compared. Concentrations of O-desmethyltramadol differed in the four genotype groups. Median (1/3 quartile) area under the concentration-time curves for (+)O-desmethyltramadol were 0 (0/11.4), 38.6 (15.9/75.3), 66.5 (17.1/118.4), and 149.7 (35.4/235.4) ng center dot h/ml for PMs, HZ/IMs, EMS, and UMs (P < 0.001). Comedication with CYP2D6 inhibitors decreased (+) O-clesmethyltramadol concentrations (P < 0.01). In PMs, non-response rates to tramadol treatment increased fourfold compared with the other genotypes (P < 0.001). In conclusion, CYP2D6 genotype determined concentrations of O-clesmethyltramadol enantiomers and influenced efficacy of tramadol treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available